MedTrace Logo

TAF in Early/Middle Pregnancy With CHB

NCT07668934 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 816

Last updated 2026-06-25

No results posted yet for this study

Summary

The goal of this clinical trial is to study the efficacy and safety of Tenofovir alafenamide (TAF) vs Tenofovir disoproxil fumarate(TDF) in early and middle pregnancy with chronic hepatitis B.

Conditions

  • Hepatitis B Infection
  • Pregnant Women
  • Early Pregnancy

Interventions

DRUG

TAF

Taking TAF from early or middle pregnancy

DRUG

TDF

Taking TDF from early or middle pregnancy

Sponsors & Collaborators

  • Second Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Qingyuan People's Hospital

    collaborator OTHER

  • The Third Affiliated Hospital of Guangzhou Medical University

    lead OTHER

Principal Investigators

  • Panpan Zhai · The Third Affiliated Hospital of Guangzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2027-03-30
Completion
2028-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07668934 on ClinicalTrials.gov